Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (101-110 of 165) with videos related to

Pageof 17
Sort By:
Haematologica|December 16, 2017
Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
American Journal of Hematology|July 31, 2018
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remissionFrancesca Lorentino, Myriam Labopin, Massimo Bernardi, et al.
Cancer|December 17, 2013
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMoshe Yeshurun, Myriam Labopin, Didier Blaise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2012
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Avichai Shimoni, et al.
British Journal of Haematology|May 21, 2025
Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programmeHenry Wood, Jenny O'Nions, Wei Yee Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2023
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, et al.
Blood|May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Haematologica|August 4, 2009
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionBella Patel, Keiren E Kirkland, Richard Szydlo, et al.
Pageof 17

Showing results (101-110 of 165) with videos related to

Sort By:
Pageof 17
Haematologica|December 16, 2017
Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
American Journal of Hematology|July 31, 2018
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remissionFrancesca Lorentino, Myriam Labopin, Massimo Bernardi, et al.
Cancer|December 17, 2013
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationMoshe Yeshurun, Myriam Labopin, Didier Blaise, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasiaSudhir Tauro, Charles Craddock, Karl Peggs, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2012
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Avichai Shimoni, et al.
British Journal of Haematology|May 21, 2025
Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programmeHenry Wood, Jenny O'Nions, Wei Yee Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2023
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working PartyAli Bazarbachi, Myriam Labopin, Tobias Gedde-Dahl, et al.
Blood|May 31, 2002
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionSuparno Chakrabarti, Stephen Mackinnon, Raj Chopra, et al.
Haematologica|August 4, 2009
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remissionBella Patel, Keiren E Kirkland, Richard Szydlo, et al.
Pageof 17